Bayer AG (Xetra: BAYN) raised its 2026 profit outlook after third-quarter Pharmaceuticals sales reached €4.68 billion, up 6.4% after adjusting for currency and portfolio changes, and EBITDA before special items in the division increased 23.6% to €1.29 billion. Group sales reached €10.05 billion and EBITDA before special items increased 6.9% to €1.62 billion, sending Bayer shares about 5% higher on November 3.
The strongest evidence of change comes from Bayer’s newer medicines. Prostate-cancer drug Nubeqa increased sales by 58.3% on a currency- and portfolio-adjusted basis and generated approximately €1 billion during the quarter alone, while kidney and heart-failure medicine Kerendia grew 64.9% and exceeded €1 billion of revenue across the latest 12 months.
That growth is arriving as older blockbusters decline. Eylea and Xarelto sales fell materially because of generic competition and patent expiration, forcing Bayer to replace mature products quickly enough to prevent the pharmaceutical division from returning to contraction. Management now argues that Pharma has entered a new growth cycle, an important claim for a company whose valuation has been dominated for years by Monsanto debt and Roundup litigation.
Why are Nubeqa and Kerendia so important to Bayer’s turnaround?
Nubeqa is becoming one of Bayer’s most important growth products as adoption expands across prostate-cancer treatment settings. Sales increased across all regions, with particularly strong United States volume growth.
Kerendia provides another significant growth platform in chronic kidney disease and heart failure. Unlike a conventional mature cardiovascular product, the medicine is still expanding its addressable patient population and geographic penetration.
These products matter because Bayer faces simultaneous declines in Xarelto and Eylea. Every euro of new revenue does not automatically become net growth if older franchises are losing comparable amounts.
The Q3 result suggests the replacement cycle is becoming more favourable. Pharmaceuticals grew 6.4% on an adjusted basis and expanded its EBITDA margin to 27.6%, up 3.5 percentage points.
Has Bayer genuinely entered a new pharmaceutical growth cycle?
Management believes it has reached a turning point, and the current data support that claim more strongly than they did a year ago. Pharmaceutical EBITDA growth of 23.6% is materially faster than sales, indicating operating leverage as newer products scale.
The Radiology business also performed well, reducing reliance on only two medicines. Beyonttra, Bayer’s cardiomyopathy treatment, generated sales around five times the prior-year level after its European launch, although the absolute revenue base remains much smaller.
The challenge remains product concentration. Nubeqa and Kerendia need to continue growing rapidly while pipeline medicines advance far enough to become meaningful contributors before today’s growth engines mature.
Asundexian and other pipeline programmes therefore remain strategically important even if they contribute little current revenue. Bayer needs a sequence of launches rather than one successful replacement cycle.
Why did Bayer still report a €672m net loss?
Strong adjusted operating performance did not translate into positive statutory profit because Bayer recognised impairment charges and other financial effects. Group net income was negative €672 million despite higher EBITDA before special items.
Core earnings per share fell to €0.31, influenced by financial-result and tax effects. This shows why the 5% share-price rally should not be interpreted as a complete earnings recovery across every accounting measure.
Adjusted EBITDA removes selected special items to show underlying business performance, but impairments still represent economic information. They indicate that assets previously recorded at higher values are now expected to generate less benefit.
Investors should therefore keep both measures in view. Operational momentum is improving, while the consolidated group still carries financial and legacy burdens that prevent clean conversion into statutory earnings.
Why is free cash flow still negative?
Third-quarter free cash flow was negative €293 million, partly because Bayer continues making litigation-related payments. For the first nine months, Chief Executive Officer Bill Anderson said free cash flow was around negative €3 billion because of known settlement obligations.
This is one of the clearest ways Monsanto continues affecting the company long after the acquisition. Pharmaceutical growth can improve operating earnings while legal payments simultaneously consume cash.
Bayer nevertheless improved its full-year free-cash-flow outlook and reduced expected year-end net financial debt. Net debt stood at approximately €31.08 billion at the end of September.
Debt reduction matters because the $63 billion Monsanto acquisition left Bayer with a balance sheet far more leveraged than the pre-deal company. Every euro spent on litigation or interest is capital unavailable for pipeline investment, acquisitions, dividends or faster deleveraging.
What would the proposed $7.25bn Roundup settlement actually solve?
Bayer is seeking court approval for a proposed $7.25 billion settlement intended to address a large portion of outstanding United States Roundup litigation. Anderson said he expects a decision before Christmas and indicated the remaining number of individual cases would be much smaller if approval is granted.
The company still faces approximately 65,000 claims in state and federal courts from plaintiffs alleging they developed non-Hodgkin lymphoma or other cancers after Roundup exposure. Bayer disputes those allegations and maintains that scientific studies support the safety of glyphosate.
These are disputed legal claims rather than established findings that Roundup causes cancer. The investment issue is the financial uncertainty created by years of litigation, regardless of how individual scientific and legal arguments are ultimately resolved.
Court approval would provide greater visibility but would not necessarily eliminate every future claim or litigation expense. Investors should therefore treat the settlement as a potentially major reduction in uncertainty rather than an instantaneous end to the Monsanto problem.
Why did Bayer separate the US Roundup business into Ruveon?
Following a United States Supreme Court victory during June, Bayer moved its U.S. Roundup activities into an internally separate unit known as Ruveon. The restructuring is intended to ring-fence management and operational responsibility around a business carrying unusual litigation exposure.
Creating a separate unit does not itself eliminate Bayer’s legal obligations. It can, however, provide clearer governance and make future strategic alternatives easier to evaluate.
The action also prevents Roundup from consuming the entire corporate narrative. Bayer wants investors to focus increasingly on pharmaceuticals, agriculture innovation and consumer health rather than assessing every quarterly result primarily through litigation.
That repositioning will succeed only if legal cash outflows fall materially. Corporate structures can clarify accountability, but investors ultimately need settlement payments and claim counts to decline.
Why is Crop Science still a problem despite the pharma rebound?
Crop Science sales declined 2.4% on a currency- and portfolio-adjusted basis during the seasonally small third quarter, while EBITDA before special items fell 41.3% to €101 million. The agricultural business therefore provided little support for the strong Pharmaceuticals result.
The nine-month picture is better, with management reporting growth around 3.5% and strong Seeds and Traits performance. Corn globally and soybeans in the United States have gained momentum, partly offsetting weaker crop-protection products.
Generic competition, regulatory product exits and difficult weather conditions continue affecting crop protection. This business mix makes Bayer fundamentally different from a pure pharmaceutical company because agriculture introduces commodity, weather and regulatory variables unrelated to medicine demand.
Portfolio complexity remains one reason investors have repeatedly debated whether Bayer should separate major divisions. Management has resisted a full breakup while simplifying operations internally, meaning the conglomerate discount remains part of the investment debate.
Is Bayer’s €31bn debt still too high?
Net financial debt of €31.08 billion is lower than earlier levels but remains large relative to Bayer’s current equity valuation and annual free cash generation. The company needs continued operating improvement and reduced litigation payments to accelerate deleveraging.
Higher interest rates make that challenge more important because refinancing debt becomes more expensive. Bayer’s improved profit outlook helps, but current free cash flow still demonstrates how slowly accounting earnings can turn into balance-sheet repair.
Asset sales or structural actions could accelerate debt reduction, although management has increasingly emphasised operational execution rather than a large corporate breakup. Investors should therefore judge progress primarily through annual cash flow and net debt rather than strategic speculation.
A sustained pharmaceutical growth cycle would materially improve the picture. Higher-margin medicine sales can create cash that reduces leverage without sacrificing investment in the pipeline.
Why did Bayer shares rally 5% despite all these unresolved risks?
The market had spent years pricing Bayer around litigation, debt and patent-expiration risk. Evidence that Pharmaceuticals can grow again therefore carries disproportionate value because it changes the assumptions around future cash generation.
The new full-year adjusted core earnings outlook of approximately €9.8 billion to €10.3 billion is above the previous range, while pharmaceutical margins are also expected to be stronger. Investors received both better current performance and a nearer potential resolution point for the Roundup settlement.
The rally should still be interpreted in context. One strong quarter does not erase tens of billions of euros of debt or guarantee court approval of a multibillion-dollar settlement.
The share move instead suggests investors are beginning to see a path in which those legacy burdens become smaller relative to a growing pharmaceutical franchise.
What should investors watch through the end of 2026?
Roundup settlement approval is the largest immediate catalyst because it could materially reduce legal uncertainty. Any delay, rejection or significant alteration would reopen questions around future cash requirements.
Nubeqa and Kerendia sales provide the second test. Continued double-digit growth is needed to offset erosion in older products and confirm that Pharmaceuticals has genuinely entered a sustainable growth cycle.
Free cash flow and net debt provide the third. Strong adjusted EBITDA matters far more if it eventually produces cash capable of repairing the balance sheet.
Bayer’s third quarter provides some of the strongest evidence yet that the company can create a post-Monsanto growth narrative. The irony is that operational success does not remove the Monsanto shadow immediately. It simply gives Bayer a growing pharmaceutical business large enough that investors can finally imagine what the company might look like once that shadow begins to recede.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
